Obesity: a gender-view.
J Endocrinol Invest · 2024
Last updated 2026-05-28This review found that obesity affects men and women differently: men have higher obesity rates overall, but women tend to have more body fat. It also notes that women are often overrepresented in anti-obesity drug trials, though gender-specific dosing adjustments are not currently recommended for drugs like Liraglutide 3 mg. Additionally, the review highlights that gender influences how people respond to treatments like bariatric surgery, with differences in weight loss outcomes and side effects.
AI summary of the abstract below.
| Journal | J Endocrinol Invest, 2024 |
|---|---|
| Citations | 98 |
| Relative citation ratio | 25.18 |
| NIH percentile | 100 |
| Molecules | — |
| Conditions studied | Obesity |
Abstract
PURPOSE: There is a growing awareness of the importance of understanding gender differences in obesity. The aim of this short review was to revise the current evidence on anthropometric characteristics and nutritional and pharmacological aspects of obesity from a gender perspective.
METHODS: A literature search within PubMed was performed. Selected publications related to obesity and gender differences were reviewed.
RESULTS: The prevalence of obesity among men is higher than in women, but women have a higher percentage of body fat content compared to men, and gender appears to be an important factor in the manifestation of central (android) or peripheral (gynoid) obesity. In addition, while in most clinical trials, women are still underrepresented, in clinical registration trials of anti-obesity drugs, women are commonly up-represented and gender-specific analysis is uncommon. Considering that adipose tissue is one of the factors affecting the volume of distribution of many drugs, mainly lipophilic drugs, gender differences might be expected in the pharmacokinetics and pharmacodynamics of anti-obesity drugs. Indeed, although Liraglutide 3 mg, a long-acting glucagon-like peptide-1 receptor agonist, and naltrexone/bupropion display lipophilic properties, currently, a gender-dose adjustment for both these drugs administration is not recommended. In addition, despite that predicted responders to treatment offer substantial opportunities for efficient use, especially of expensive new therapies, such as anti-obesity drugs, data on gender differences to identify early responders to both these have not yet been investigated. Finally, bariatric surgery gender disparity reflects healthcare practices. Weight loss similar, but differing effects: women need more correction and face psychology challenges; men have worse physiology and fewer comorbidity improvements.
CONCLUSION: Gender differences exist in obesity prevalence and phenotype, body fat distribution, drug efficacy, clinical trial representation, and different secondary effects of bariatric surgery. Gender is an important variable in obesity analysis.
Verbatim abstract via PubMed 37740888 ↗